Ying-Chou Chen

Learn More
OBJECTIVE To explore the causal relationship between gout and Type 2 diabetes based on genetic evidence and national outpatient database. METHODS Twenty male gout patients with early-onset, gout family history, without a habit of alcohol consumption or obesity before the first attack of gout were selected from hospital in 2010; and 42 unrelated male(More)
OBJECTIVES This prospective study aimed to compare synovial ultrasound scores to conventional measures (DAS28, CRP levels) in predicting radiographic progression in patients with rheumatoid arthritis under TNF antagonist therapy. METHODS Patients with RA who received TNF antagonist therapy were enrolled, all of whom underwent clinical, laboratory, and(More)
This study investigated whether bone mineral density (BMD) affects readmission risk in patients with chronic kidney diseases (CKD) who received denosumab therapy. The study design was a retrospective case review of patients with CKD. Baseline age, sex, and body mass index were recorded for all patients included in the study. All comorbidities were recorded.(More)
OBJECTIVES To evaluate the effect of baricitinib on patient-reported outcomes (PROs) in patients with active rheumatoid arthritis (RA) and an inadequate response or intolerance to conventional synthetic disease-modifying antirheumatic drugs. METHODS In this phase III study, patients were randomised 1:1:1 to placebo (N=228), baricitinib 2 mg once daily(More)
BACKGROUND Baricitinib is an oral, reversible, selective Janus kinase 1 and 2 inhibitor. METHODS In this phase III, double-blind 24-week study, 684 biologic disease-modifying antirheumatic drug (DMARD)-naïve patients with rheumatoid arthritis and inadequate response or intolerance to ≥1 conventional synthetic DMARDs were randomly assigned 1:1:1 to placebo(More)
BACKGROUND Adjacent fracture of the cemented vertebrae result from crushed fragile trabeculae during follow-up, suggesting impaired bone marrow integrity. This study aimed to determine if anti-osteoporotic therapy can decrease the risk of adjacent fracture in patients after vertebroplasty. METHODS This retrospective study reviewed of cases of osteoporotic(More)
BACKGROUND Osteoporotic fractures are associated with mortality in postmenopausal woman. Whether raloxifen treatment after vertebroplasty can reduce mortality is unclear in this group. To compare the effect of raloxifene and no osteoporosis treatment on the risk of mortality after vertebroplasty, we designed this study. METHODS This was a retrospective(More)
  • 1